scholarly journals A stepwise approach for pharmacists: Cardiovascular risk reduction with novel antihyperglycemic agents in patients with type 2 diabetes and atherosclerotic cardiovascular disease

2020 ◽  
pp. 171516352097614
Author(s):  
Logan Underwood ◽  
William Semchuk ◽  
Lori Albers
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Risk Reduction ◽  
Atherosclerotic Cardiovascular Disease ◽  
Cardiovascular Risk Reduction ◽  
Stepwise Approach ◽  
Antihyperglycemic Agents

Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus

2017 ◽  
Vol 31 (4) ◽  
pp. 459-470 ◽  
Author(s):  
Scott L. Purga ◽  
Mandeep Sidhu ◽  
Michael Farkouh ◽  
Joshua Schulman-Marcus
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
Risk Reduction ◽  
Cardiovascular Risk Reduction

scholarly journals Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes

2020 ◽  
Vol 66 (9) ◽  
pp. 1283-1288
Author(s):  
Eduardo Bello Martins ◽  
Eduardo Gomes Lima ◽  
Fábio Grunspun Pitta ◽  
Leticia Neves Solon Carvalho ◽  
Thiago Dias de Queiroz ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Pharmacological Therapy ◽  
High Cardiovascular Risk ◽  
Cardiovascular Risk Reduction ◽  
Drug Classes ◽  
Clinical Benefits

SUMMARY The pharmacological therapy for type 2 diabetes mellitus has presented important advances in recent years, which has impacted the treatment of patients with established cardiovascular disease or with high cardiovascular risk. In this scenario, two drug classes have emerged and demonstrated clear clinical benefits: SGLT-2 inhibitors and GLP-1 agonists. The present review discusses the pharmacology, adverse effects, and clinical trials that have demonstrated the benefits of these medications in reducing cardiovascular risk.

scholarly journals 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

2020 ◽  
Vol 76 (9) ◽  
pp. 1117-1145 ◽  
Author(s):  
Sandeep R. Das ◽  
Brendan M. Everett ◽  
Kim K. Birtcher ◽  
Jenifer M. Brown ◽  
James L. Januzzi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Risk Reduction ◽  
Expert Consensus ◽  
Novel Therapies ◽  
Cardiovascular Risk Reduction ◽  
Consensus Decision

scholarly journals LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES —   A MANDATE FOR CARDIOLOGIST AND INTERNIST

2018 ◽  
pp. 89-92
Author(s):  
S. V. Nedogoda
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Risk Reduction ◽  
Pleiotropic Effect ◽  
Successful Management ◽  
Cardiovascular Risk Reduction ◽  
Glucose Lowering

The data from a range of large trials (LEADER, EMPA-REG, CANVAS) show evidently the practical use of the modern glucose lowering drugs usage for successful management of cardiovascular risk in type 2 diabetes (DM2) patients. The article is focused on analysis and review of possible mechanisms and benefits of cardiovascular risk reduction in DM2 with prescription of the antagonist of glucagonlike peptide 1 — liraglutide (Victoza®).

Sign in / Sign up

Export Citation Format

Share Document